Skip to main content
. 2021 Mar 25;10(3):29. doi: 10.1167/tvst.10.3.29

Figure 4.

Figure 4.

Percent reduction in fluid from baseline during matched phase. (A) Reduction in intraretinal fluid (IRF) from baseline in treatment agnostic (gray diamond), brolucizumab (blue circle), and aflibercept (red square) groups. (B) Reduction in subretinal fluid (SRF) from baseline in treatment agnostic (gray diamond), brolucizumab (blue circle), and aflibercept (red square) groups.